Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange



    VANCOUVER, Nov. 6 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) is pleased to announce that the Toronto Stock Exchange (TSX) has
conditionally approved the Company's application for listing its common shares
on the TSX. Listing on the TSX will be subject to the Company filing
satisfactory final documentation with the TSX. The Company will issue a news
release when final listing approval has been granted by the TSX.

    About Response Biomedical

    Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP(R) Platform for clinical and
environmental applications. RAMP(R) represents a new paradigm in diagnostics
that provides high sensitivity and reliable information in minutes. It is
ideally suited to both point-of-care testing and laboratory use. The RAMP(R)
system consists of a portable fluorescent reader and single-use disposable
test cartridges, and has the potential to be adapted to more than 250 medical
and non-medical tests currently performed in laboratories. RAMP(R) clinical
tests are commercially available for the early detection of heart attack and
congestive heart failure.
    In late 2006, the Company formed a strategic alliance with 3M Company to
commercialize rapid infectious disease tests. In the non-clinical market, RAMP
Tests are currently provided for the environmental detection of West Nile
Virus, and Biodefense applications including the rapid on-site detection of
anthrax, smallpox, ricin and botulinum toxin. Several other product
applications are under development. The Company has achieved CE Marking and
its Quality Management System is registered to ISO 13485: 2003 and ISO 9001:
2000.
    Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at www.responsebio.com.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.

    Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.

    Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, financial risks that
would affect our operations such as our available working capital and cash
flows and whether and for how long available funds will be sufficient to fund
our operations and our ability to raise additional capital as and when needed;
relationships with strategic alliance partners to develop and commercialize
products; technological changes that impact our existing products or our
ability to develop and commercialize our products; our ability to obtain and
enforce timely patent and other intellectual property protection for our
technology and products; liability for patent, product liability and other
claims asserted against us; commercialization limitations imposed by patents
owned or controlled by third parties; adverse results or unexpected delays in
product development and clinical trials; our ability to retain, and our
reliance upon, alliance partners; our ability to effectively and efficiently
manage the planned growth of our operations; our ability to obtain, and the
timing of, necessary regulatory approvals; market acceptance of our products
and the size of our markets; changes in business strategy or development
plans; and other factors referenced in our annual report on Form 40-F and
other filings with Canadian and United States securities regulatory
authorities.

    Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments.





For further information:

For further information: Bill Wickson, Manager, Investor Relations,
Response Biomedical Corporation, Tel (604) 456-6073, Email:
bwickson@responsebio.com; Brian Korb, Vice President, The Trout Group LLC,
Tel: (646) 378-2923, Email: bkorb@troutgroup.com

Organization Profile

RESPONSE BIOMEDICAL CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890